On June 17, 2026, the trial titled "Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI-2 Trial" was listed as recruiting. The study, registered as NCT07361783, does not have a designated phase. Bivalirudin, an approved anticoagulant, is referenced within the trial context involving primary percutaneous coronary intervention for STEMI patients.
The trial's current status is recruiting, meaning it is actively enrolling participants as of the listed date. No results have been posted for this trial at this time. The study focuses on pre-hospital heparin loading in ST-elevation myocardial infarction patients who will undergo primary PCI.
Details on the trial's design, comparator arms, and specific role of bivalirudin within the protocol are available through the official registry listing. As with any actively recruiting trial, outcomes and findings are not yet available and will be reported upon completion or interim analysis, according to standard clinical trial practice.
Readers interested in the pharmacology, approved uses, and background of bivalirudin can consult the compound overview for further context.